• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bristol-Myers Squibb (NY:BMY)

    59.86 -0.07 (-0.12%)
    Official Closing Price Updated: 7:00 PM EST, Feb 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Bristol-Myers Squibb

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    86 87 Next >
    News headline image
    The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call
    Bristol-Myers Squibb’s fourth quarter saw continued momentum in its growth portfolio, which management credited as the primary driver behind the company’s positive results. CEO Christopher Boerner... 
    Via StockStory
    Topics Earnings
    News headline image
    Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
    As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the... 
    Via Finterra
    Topics Economy Intellectual Property
    Bristol Myers Squibb Co (NYSE:BMY) Beats Q4 2025 Earnings Estimates and Provides Strong 2026 Outlook ↗
    Via Chartmill
    Bristol-Myers Squibb Co (NYSE:BMY) Shows Strong Technical Setup for Potential Breakout ↗
    Via Chartmill
    News headline image
    Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
    Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the... 
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
    The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
    As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a... 
    Via Finterra
    Topics ETFs Economy Initial Public Offering
    News headline image
    BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus
    Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue... 
    Via StockStory
    News headline image
    Why Bristol Myers Squibb Stock Topped the Market Today ↗
    At the end of last year, the company did particularly well with its lineup of newer medications. 
    Via The Motley Fool
    News headline image
    Bristol Myers (BMY) Q4 2025 Earnings Transcript ↗
    Bristol Myers (BMY) Q4 2025 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025
    Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue guidance... 
    Via StockStory
    News headline image
    Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    Bristol Myers Q4 Earnings Preview: Profits Under Pressure Even As Wall Street Bets On 2026 Pipeline ↗
    The drugmaker is relying on its newer pipeline to offset Eliquis' upcoming patent cliff in 2028. 
    Via Stocktwits
    Topics Artificial Intelligence Intellectual Property Workforce
    News headline image
    Bristol-Myers Squibb Earnings: What To Look For From BMY
    Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results this Thursday before the bell. Here’s what to expect. 
    Via StockStory
    News headline image
    Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs
    As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those... 
    Via MarketMinute
    Topics Economy Government Intellectual Property
    News headline image
    The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
    The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative... 
    Via MarketMinute
    Topics ETFs Government Initial Public Offering
    News headline image
    3 Top Dividend Stocks Yielding More Than 4% to Buy Hand Over Fist This Year ↗
    All three can provide you with solid, consistent income. 
    Via The Motley Fool
    Topics Artificial Intelligence Intellectual Property World Trade
    News headline image
    3 Unpopular Stocks That Concern Us
    When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
    Via StockStory
    News headline image
    The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
    As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the... 
    Via Finterra
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
    The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market... 
    Via Finterra
    Topics Economy Initial Public Offering
    News headline image
    2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
    Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps. 
    Via The Motley Fool
    Topics ETFs Intellectual Property World Trade
    News headline image
    AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term. ↗
    Artificial intelligence may be all the rage in the technology sector, but it's also having a huge impact on healthcare. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
    Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing. 
    Via The Motley Fool
    News headline image
    Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth
    NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the... 
    Via MarketMinute
    Topics Earnings Economy Intellectual Property
    News headline image
    The Best Stocks to Invest $1,000 in Right Now ↗
    Large, well-run dividend-paying companies with attractive yields are out there if you look hard enough. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
    From Bristol Myers Squibb
    Via Business Wire
    News headline image
    2 Dividend Stocks to Buy and Hold For 10 Years ↗
    They are unlikely to resort to dividend cuts anytime soon. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    2 Buffett Stocks to Load Up On—And 1 to Ditch ↗
    Via MarketBeat
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    86 87 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.